Drug intelligence / Profile preview

VCC-004

Development stage: Preclinical
Lead developer: Vaccentis
Modality: Vaccines & Immunotherapeutics

Overview

VCC-004 is a therapeutic cancer vaccine being developed by Vaccentis for the treatment of lung cancer. Currently in the preclinical stage of research, it is part of a pipeline of autologous tumor vaccines. While specific details for VCC-004 are limited, the Vaccentis platform generally focuses on inducing a specific immune response against a patient's tumor by utilizing an individual antigen profile, thereby enabling the immune system to recognize and attack malignant cells.

Beyond the preview

Go deeper on VCC-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VCC-004.

Explore the full profile